

Supplementary Materials : (E)-3-(3-(4-morpholinophenyl)acryloyl)-2H-chromen-2-one

Hery Suwito, Helda Dwi Hadiyanti, Kautsar Ul Haq, Alfinda Novi Kristanti, and Miratul Khasanah




Figure S1. FTIR spectra of 3-acetyl-2H-chromen-2-one (compound 3)




Figure S2. HRESIMS spectra of 3-acetyl-2H-chromen-2-one (compound **3**)




Figure S4. ^{13}C -NMR spectra of 3-acetyl-2H-chromen-2-one (compound 3)




Figure S5. FTIR spectra of (E)-3-(3-(4-morpholinophenyl)acryloyl)-2H-chromen-2-one (compound 5)




Figure S6. HRESIMS spectra of (*E*)-3-(3-(4-morpholinophenyl)acryloyl)-2H-chromen-2-one (compound 5)




Figure S7-a. ¹H NMR spectra of (E)-3-(3-(4-morpholinophenyl)acryloyl)-2H-chromen-2-one (compound 5)




Figure S7-b. ¹H NMR spectra of (E)-3-(3-(4-morpholinophenyl)acryloyl)-2H-chromen-2-one (compound 5)




Figure S8. ¹³C NMR APT spectra of (E)-3-(3-(4-morpholinophenyl)acryloyl)-2H-chromen-2-one (Compound 5)




Figure S9. HMQC spectra of (*E*)-3-(3-(4-morpholinophenyl)acryloyl)-2H-chromen-2-one (Compound 5)




Figure S10. HMBC spectra of (*E*)-3-(3-(4-morpholinophenyl)acryloyl)-2H-chromen-2-one (Compound 5)




Figure S10. HMBC spectra of (*E*)-3-(3-(4-morpholinophenyl)acryloyl)-2H-chromen-2-one (Compound 5)

Table S1. Anticancer evaluation data of the title compound using MTT assay against T47D and HeLa cancer cells line.

Tested compound	Concentration (µg/mL)	Absorbance			% Viability	SD	IC ₅₀ (µg/mL)	IC ₅₀ (µM)
		I	II	III				
Against T47D cells								
(E)-3-(3-(4-morpholinophenyl)acryloyl)-2H-chromen-2-one	100	0.618	0.601	0.611	66.00	0.009	325.745	0.901
	50	0.685	0.731	0.744	79.81	0.031		
	25	0.720	0.729	0.755	81.65	0.018		
	12.5	0.753	0.812	0.806	88.64	0.032		
	6.25	0.807	0.860	0.831	93.95	0.026		
	3.125	0.821	0.874	0.859	96.30	0.027		
	1.5625	0.876	0.950	0.941	105.21	0.040		
Doxorubicin	1	0.366	0.404	0.426	44.20	0.030	0.111	-
	0.5	0.163	0.158	0.162	4.05	0.003		
	0.25	0.241	0.249	0.232	17.51	0.009		
	0.125	0.462	0.437	0.453	52.98	0.013		
	0.0625	0.603	0.588	0.644	80.18	0.029		
	0.03125	0.599	0.640	0.622	81.64	0.021		
Against HeLa cells								
(E)-3-(3-(4-morpholinophenyl)acryloyl)-2H-chromen-2-one	100	0.650	0.724	0.695	75.82	0.037	839.083	2.321
	50	0.689	0.681	0.710	76.30	0.015		
	25	0.648	0.722	0.734	77.37	0.047		
	12.5	0.693	0.735	0.755	80.86	0.03		
	6.25	0.780	0.769	0.815	88.90	0.024		
	3.125	0.829	0.848	0.810	94.30	0.019		
	1.5625	0.762	0.857	0.913	96.29	0.076		
Doxorubicin	20	0.398	0.415	0.383	53.16	0.016	1,199	-
	10	0.560	0.560	0.383	61.83	0.102		
	5	0.480	0.485	0.470	66.54	0.008		
	2.5	0.447	0.421	0.409	57.70	0.019		
	1.25	0.388	0.407	0.380	51.99	0.014		
	0.625	0.327	0.332	0.326	41.35	0.003		